Abstract: Furmonertinib is now covered by the national medical insurance and will bring great benefits to China

January 1, 2022 marked the first day that the latest version of China's national medical insurance catalog would be implemented. Furmonertinib Mesilate was successfully included in the medical insurance prescriptions at Shanghai Pulmonary Hospital, the Second Affiliated Hospital of Zhejiang University School of Medicine, the First Affiliated Hospital of Zhejiang University School of Medicine, Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, the Affiliated Hospital of Qingdao University, Taizhou Central Hospital, Linyi People's Hospital and many other hospitals.

According to the supply guarantee requirements negotiated by the National Healthcare Security Administration, Furmonertinib has been added to "dual-channel management" in more than 20 provinces and cities, including Jiangsu, Fujian, Guangdong, Shenzhen, Hunan, Hubei, Guangxi, Shaanxi, Jilin, Liaoning, Guizhou, Qingdao, Yantai, Jinan, Ningxia and Weihai, and can be reimbursed through medical insurance at designated pharmacies, making purchasing more convenient for patients.